Literature DB >> 12866421

Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens.

T Henics1, B Winkler, U Pfeifer, S R Gill, M Buschle, A von Gabain, A L Meinke.   

Abstract

Taking advantage of whole genome sequences of bacterial pathogens in many thriving diseases with global impact, we developed a comprehensive screening procedure for the identification of putative vaccine candidate antigens. Importantly, this procedure relies on highly representative small-fragment genomic libraries that are expressed to display frame-selected epitope-size peptides on a bacterial cell surface and to interact directly with carefully selected disease-relevant high-titer sera. Here we describe the generation of small-fragment genomic libraries of Gram-positive and Gram-negative clinically significant pathogens, including Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus pneumoniae, Enterococcus faecalis, Helicobacter pylori, Chlamydia pneumoniae, the enterotoxigenic Escherichia coli, and Campylobacter jejuni. Large-scale sequencing revealed that the libraries, which provide an average of 20-fold coverage, were random and, as demonstrated with two S. aureus libraries, highly representative. Consistent with the comprehensive nature of this approach is the identification of epitopes that reside in both annotated and putatively novel open reading frames. The use of these libraries therefore allows for the rapid and direct identification of immunogenic epitopes with no apparent bias or difficulty that often associate with conventional expression methods.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866421     DOI: 10.2144/03351dd03

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  6 in total

1.  Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.

Authors:  Francesco Doro; Sabrina Liberatori; Manuel J Rodríguez-Ortega; Cira D Rinaudo; Roberto Rosini; Marirosa Mora; Maria Scarselli; Emrah Altindis; Romina D'Aurizio; Maria Stella; Immaculada Margarit; Domenico Maione; John L Telford; Nathalie Norais; Guido Grandi
Journal:  Mol Cell Proteomics       Date:  2009-04-28       Impact factor: 5.911

2.  Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.

Authors:  Andrea Fritzer; Beatrice M Senn; Duc Bui Minh; Markus Hanner; Dieter Gelbmann; Birgit Noiges; Tamás Henics; Kai Schulze; Carlos A Guzman; John Goodacre; Alexander von Gabain; Eszter Nagy; Andreas L Meinke
Journal:  Infect Immun       Date:  2010-07-12       Impact factor: 3.441

3.  Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae.

Authors:  Urban Lundberg; Beatrice M Senn; Wolfgang Schüler; Andreas Meinke; Markus Hanner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

4.  Adhesive polypeptides of Staphylococcus aureus identified using a novel secretion library technique in Escherichia coli.

Authors:  Riikka Kylväjä; Matti Kankainen; Liisa Holm; Benita Westerlund-Wikström
Journal:  BMC Microbiol       Date:  2011-05-27       Impact factor: 3.605

5.  Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies.

Authors:  Carmen Giefing; Andreas L Meinke; Markus Hanner; Tamás Henics; Minh Duc Bui; Dieter Gelbmann; Urban Lundberg; Beatrice M Senn; Michael Schunn; Andre Habel; Birgitta Henriques-Normark; Ake Ortqvist; Mats Kalin; Alexander von Gabain; Eszter Nagy
Journal:  J Exp Med       Date:  2007-12-31       Impact factor: 14.307

Review 6.  The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections?

Authors:  Carmen Giefing; Eszter Nagy; Alexander von Gabain
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.